Takeda Pharma, Apr-Jun (1Q) Net Income Increases by 30%

About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.

Wed Jul 30, 2025 3:30 pm JST Earnings

4502 Takeda Pharmaceutical Company Limited 【IFRS】

Earnings Report

Takeda Pharmaceutical Company Limited <4502> [TSE Prime] announced its financial results (based on IFRS) after the market closed on July 30th (15:30). The consolidated net income for the first quarter of the fiscal year ending March 2026 (April to June) expanded 124 billion yen, an increase 30.4% compared to the same period last year. Progress toward the full-year plan of 228 billion yen was 54.5%, almost the same as the five-year average of 53.0%.

In the most recent three-month period, from April to June (1Q), the operating profit margin rose from 13.8% in the same period last year to 16.7%.

Kabutan News

Actual Results

Accumulated Results 1st Quarter

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Progress Rate vs. First Half	Announce	Accounting Standards
Apr - Jun, 2023	1,058,618	168,571	135,033	89,395	57.5	345.8	Jul 27, 2023	IFRS
Apr - Jun, 2024	1,207,990	166,329	136,604	95,248	60.7	53.4	Jul 31, 2024	IFRS
Apr - Jun, 2025	1,106,685	184,566	150,630	124,243	79.4	ー	Jul 30, 2025	IFRS
YoY	-8.4%	+11.0%	+10.3%	+30.4%	+30.8%

Current Period Guidance

H1 Results

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Apr - Sep, 2024	2,384,028	350,576	255,976	187,294	118.9	98	Oct 31, 2024	IFRS
Apr - Sep, 2025 Guidance	ー	ー	ー	ー	－	100	May 8, 2025	IFRS
YoY	－	－	－	－	－

Current Period Guidance

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Mar, 2024	4,263,762	214,075	52,791	144,067	92.1	188	May 9, 2024	IFRS
Mar, 2025	4,581,551	342,586	175,084	107,928	68.4	196	May 8, 2025	IFRS
Mar, 2026 Guidance	4,530,000	475,000	307,000	228,000	144.3	200	May 8, 2025	IFRS
YoY	-1.1%	+38.7%	+75.3%	+111.3%	+111.1%

Quarterly Results

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Operating Profit Margin	Announce	Accounting Standards
Apr - Jun, 2024	1,207,990	166,329	136,604	95,248	60.7	13.8	Jul 31, 2024	IFRS
Jul - Sep, 2024	1,176,038	184,247	119,372	92,046	58.4	15.7	Oct 31, 2024	IFRS
Oct - Dec, 2024	1,144,124	66,942	26,407	23,789	15.1	5.9	Jan 30, 2025	IFRS
Jan - Mar, 2025	1,053,399	-74,932	-107,299	-103,155	-65.3	-7.1	May 8, 2025	IFRS
Apr - Jun, 2025	1,106,685	184,566	150,630	124,243	79.4	16.7	Jul 30, 2025	IFRS
YoY	-8.4%	+11.0%	+10.3%	+30.4%	+30.8%